case_images: PMC10438988_01
case_images: Case report timeline. 1L, first line; 2L, second line; 3L, third line.
case_images: fonc-13-1214660-g001.jpg
case_images: PMC10438988_01_fonc-13-1214660-g001.jpg
case_images: f1
case_images: BC of the right breast ( Figure 1 ).
case_images: Baseline mammography showing pathological lump in the right breast.
case_images: fonc-13-1214660-g002.jpg
case_images: PMC10438988_01_fonc-13-1214660-g002.jpg
case_images: f2
case_images: Breast and axillary lymph node ultrasound scan showed a nodule with irregular margins (23 mm diameter) in the upper-outer quadrant of the right breast. Bilateral mammography demonstrated radiopacity in the right breast and fine-needle aspiration biopsy retrieved malignant cells (C5) ( Figure 2 ).
case_images: First evidence of metastatic disease on baseline PET-CT scan.
case_images: fonc-13-1214660-g003.jpg
case_images: PMC10438988_01_fonc-13-1214660-g003.jpg
case_images: f3
case_images: PET-CT scan showed involvement of skin of the left breast, increased uptake in multiple lymph nodes of the left axilla and left internal mammary, and bone infiltrations (fourth and sixth left ribs) ( Figure 3 ). Pathological examination showed skin metastasis from breast carcinoma (ER: 0%, PgR: 0%, Ki-67: 80%, HER2-neu: 0).
case_images: PMC10438988_02
case_images: PMC10438988_03
case_images: (A) CT scan images of left chest wall disease progression at enrolment in the IMpassion131 trial. (B) CT scan images at enrolment in CLAG525B2101 trials. (C) Complete response after 6 months of treatment with olaparib; no contrast enhancement at PET-CT scan.
case_images: fonc-13-1214660-g004.jpg
case_images: PMC10438988_04_fonc-13-1214660-g004.jpg
case_images: f4
case_images: In February 2020, as a patient with a germline BRCA mutation who had received no more than two previous chemotherapy regimens for metastatic disease, she was eligible for olaparib (300 mg twice daily) therapy ( Figure 4B ). There was no evidence of increased uptake on PET/CT scan ( Figure 4C ).
case_images: PMC10438988_04
case_images: (A) CT scan images of left chest wall disease progression at enrolment in the IMpassion131 trial. (B) CT scan images at enrolment in CLAG525B2101 trials. (C) Complete response after 6 months of treatment with olaparib; no contrast enhancement at PET-CT scan.
case_images: fonc-13-1214660-g004.jpg
case_images: PMC10438988_04_fonc-13-1214660-g004.jpg
case_images: f4
case_images: In February 2020, as a patient with a germline BRCA mutation who had received no more than two previous chemotherapy regimens for metastatic disease, she was eligible for olaparib (300 mg twice daily) therapy ( Figure 4B ). There was no evidence of increased uptake on PET/CT scan ( Figure 4C ).